Compare Cipla with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs NATCO PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA NATCO PHARMA CIPLA/
NATCO PHARMA
 
P/E (TTM) x 35.6 34.4 103.6% View Chart
P/BV x 4.1 4.9 84.5% View Chart
Dividend Yield % 0.5 0.7 71.7%  

Financials

 CIPLA   NATCO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
NATCO PHARMA
Mar-19
CIPLA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs586849 69.0%   
Low Rs357557 64.1%   
Sales per share (Unadj.) Rs207.0573.8 36.1%  
Earnings per share (Unadj.) Rs18.6176.0 10.6%  
Cash flow per share (Unadj.) Rs33.2198.2 16.7%  
Dividends per share (Unadj.) Rs4.006.25 64.0%  
Dividend yield (eoy) %0.80.9 95.5%  
Book value per share (Unadj.) Rs195.5842.7 23.2%  
Shares outstanding (eoy) m806.3536.50 2,209.2%   
Bonus/Rights/Conversions ESOSBB-  
Price / Sales ratio x2.31.2 185.8%   
Avg P/E ratio x25.34.0 634.3%  
P/CF ratio (eoy) x14.23.5 400.5%  
Price / Book Value ratio x2.40.8 288.9%  
Dividend payout %21.53.6 605.7%   
Avg Mkt Cap Rs m379,91225,660 1,480.6%   
No. of employees `00025.85.0 521.4%   
Total wages/salary Rs m30,2703,559 850.5%   
Avg. sales/employee Rs Th6,459.64,225.3 152.9%   
Avg. wages/employee Rs Th1,171.2718.0 163.1%   
Avg. net profit/employee Rs Th580.21,295.9 44.8%   
INCOME DATA
Net Sales Rs m166,94920,945 797.1%  
Other income Rs m3,4421,302 264.4%   
Total revenues Rs m170,39122,247 765.9%   
Gross profit Rs m32,0607,948 403.4%  
Depreciation Rs m11,747810 1,450.2%   
Interest Rs m1,974193 1,022.6%   
Profit before tax Rs m21,7828,247 264.1%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3121,823 346.2%   
Profit after tax Rs m14,9956,424 233.4%  
Gross profit margin %19.237.9 50.6%  
Effective tax rate %29.022.1 131.1%   
Net profit margin %9.030.7 29.3%  
BALANCE SHEET DATA
Current assets Rs m117,03823,472 498.6%   
Current liabilities Rs m43,9317,287 602.9%   
Net working cap to sales %43.877.3 56.7%  
Current ratio x2.73.2 82.7%  
Inventory Days Days9692 103.8%  
Debtors Days Days8588 96.4%  
Net fixed assets Rs m107,42418,648 576.1%   
Share capital Rs m1,613365 441.8%   
"Free" reserves Rs m156,01834,525 451.9%   
Net worth Rs m157,63030,760 512.5%   
Long term debt Rs m23,6930-   
Total assets Rs m236,62643,031 549.9%  
Interest coverage x12.043.7 27.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.5 145.0%   
Return on assets %7.215.4 46.6%  
Return on equity %9.520.9 45.6%  
Return on capital %12.827.4 46.8%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03611,536 485.7%   
Fx outflow Rs m6,7642,939 230.1%   
Net fx Rs m49,2728,597 573.1%   
CASH FLOW
From Operations Rs m30,6856,688 458.8%  
From Investments Rs m1,040-6,122 -17.0%  
From Financial Activity Rs m-29,488-509 5,793.4%  
Net Cashflow Rs m2,34066 3,545.8%  

Share Holding

Indian Promoters % 16.0 52.0 30.7%  
Foreign collaborators % 20.8 1.5 1,415.0%  
Indian inst/Mut Fund % 12.2 7.8 155.6%  
FIIs % 23.7 16.6 142.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 26.0 100.8%  
Shareholders   161,166 25,395 634.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WYETH  CADILA HEALTHCARE  SUVEN LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 22, 2021 (Close)

TRACK CIPLA

CIPLA - FULFORD INDIA COMPARISON

COMPARE CIPLA WITH

MARKET STATS